Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines (1.1 or 1.2) (ICHD-3 2013), with a history of migraine headaches of at least 1 year prior to screening, and migraine onset prior to age 50.~Exclusion Criteria:~* Are currently enrolled in or have participated within the last 30 days or within 5 half-lives (whichever is longer) in a clinical trial involving an investigational product.~* Current use or prior exposure to Galcanezumab or other antibodies to CGRP or its receptor.~* Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins, or to Galcanezumab and the excipients in the investigational product.~* History of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 120 milligrams (mg) Galcanezumab (Type: EXPERIMENTAL): 120 mg galcanezumab (LY2951742) administered subcutaneously (SC) once a month for 6 months.
- 240 mg Galcanezumab (Type: EXPERIMENTAL): 120 mg galcanezumab (LY2951742) administered SC once a month for 6 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered SC once a month for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).